a study on Solid Tumor Refractory Tumor Recurrent Tumor CNS Malignancies
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
Pediatric Solid Tumor Refractory Tumor Recurrent Tumor CNS Malignancies relapsed pediatric solid tumors unspecified childhood solid tumor brain and central nervous system tumors Ramucirumab Endothelial Growth Factors
Open to people ages 12 months to 21 years
This step makes sure spammers don’t flood our inbox
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02564198.
© 2017 The Regents of the University of California